SEPTEMBER 09, 2026
RARE TUMORS: DIAGNOSIS AND TREATMENT OF TFE-REARRANGED RENAL CELL CARCINOMA
ASCO ENDORSED ONLINE WORKSHOP
Free registration
Meet the group, explore the workshop, and get a free knowledge
By signing up, you agree to our Privacy Policy.
WATCH ONLINE
ASCO Endorsed Webinar
Webinar
09 September 2026,
09:30-11:00 (EDT, New York time)
Organizer: Bureau for Cancer Research - BUCARE

TFE-rearranged renal cell carcinoma represents a distinct and challenging subtype of kidney cancer, requiring specialized diagnostic approaches and multidisciplinary management. Despite increasing recognition, significant variability remains in clinical practice worldwide, underscoring the need for continued education and expert dialogue.
This webinar brings together a diverse panel of specialists to address key aspects of diagnosis, treatment, and patient care. Its international scope and multidisciplinary format will provide valuable insights and foster meaningful discussion among clinicians managing this rare disease.

Participants/Languages: Oncologists & pathologists from different countries / English
Registration fee
Free

Link to broadcast on YouTube
https://youtu.be/P1J7t6yuUAw
PROGRAM COMMITTEE
  • Timur Mitin,
    MD, PhD

    Professor, Radiation Oncologist, Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA
  • Maria Tretiakova,
    MD, PhD, FCAP

    Professor
    President-elect, GUPS
    GU pathology service chief
    Director, GU pathology fellowship & HMC clerkship
    Director, UWMC/HMC IHC laboratories
    University of Washington
    Seattle, WA, USA
  • Ilya Tsimafeyeu,
    MD, PhD

    Medical Oncologist,

    Director, Bureau for Cancer Research - BUCARE, Moscow / New York

  • Kadriye Başkurt,
    MD

    Medical Oncologist,

    Ankara Etlik City Hospital,

    Ankara, Turkey

  • Darya Davydova,
    PhD

    Head, Kidney Cancer Patient Group, Moscow, Russia

  • Samat Kaldarbekov,
    MD

    Medical Oncologist,
    Executive Director, Kazakhstan Cancer Society;
    Head, Day Hospital, Zhambyl Regional Multidisciplinary Oncology and Surgery Center,
    Taraz, Kazakhstan
PROGRAM
Welcome message
09.30-09.40
Sarah Bachmann, ASCO Representative
Ilya Tsimafeyeu, Director, BUCARE
Radiation Oncology
Is TFE-rearranged RCC sensitive to radiation therapy?
09.40-09.55
Timur Mitin
(radiation oncologist, USA)
Pathology Insights
Diagnostic criteria, molecular features, and reporting standards.
09.55-10.15
Maria Tretiakova
(pathologist, USA)
Medical Oncology Perspectives
Systemic treatment strategies and emerging therapies.
10.15-10.30
Kadriye Başkurt
(medical oncologist, Türkiye)
Abstract
A randomized phase 2 study of nivolumab plus ipilimumab or nivolumab plus cabozantinib as first-line therapy, with protocol-specified lenvatinib plus everolimus in the second-line, in metastatic TFE-rearranged renal cell carcinoma
10.30-10.40
Ilya Tsimafeyeu
(medical oncologist, RU/USA)
Patient Perspective
Understanding the patient journey, challenges in diagnosis, and unmet needs.
10.40-10.50
Darya Davydova
(patient, RU)
Panel Discussion & Q&A

10.50-11.00
Ilya Tsimafeyeu (medical oncologist, RU/USA)
Samat Kaldarbekov (medical oncologist, Kazakhstan)
STAY UP TO DATE
Don't miss the news of meetings, subscribe to our newsletter
All rights reserved.
“ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.”